Meet Us at the 13th Alzheimer’s & Parkinson’s Drug Development Summit
13th Alzheimer’s & Parkinson’s Drug Development Summit
March 18-20, 2025
Revere Hotel Boston Common, 200 Stuart St, Boston, MA 02116, USA
In 2025, the spotlight is on neurodegenerative drug development, driven by the triumph of Lecanemab and Donanemab, coupled with rapid advancements to enable presymptomatic diagnosis, reinvigorating the space with new targets, modalities, and technologies. Meanwhile significant advancements to target the likes of α-synuclein, NLRP3 and GBA suggest only a matter of time until a disease-modifying therapy emerges on the scene for Parkinson’s too.
Capitalizing on a new era of revitalized hope and momentum, the 13th Alzheimer's & Parkinson's Drug Development Summit returns as the only industry-focused and end-to-end meeting, with comprehensive coverage spanning early discovery through to late clinical, regulatory, and commercial development. Join us for our presentation "From Cells to Insights: Advancing Neuroscience with Tailored In Vitro Platforms" during the Target Discovery & In Vitro Validation Track (Track 1) on Day 1.
Meet us at the 13th Alzheimer’s & Parkinson’s Drug Development Summit! Our specialists are excited to discuss how Creative Biolabs can help develop and optimize your therapeutics. Feel free to leave your contact information and tell us your project needs!